BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 25789956)

  • 1. Sox17 promoter methylation in plasma DNA is associated with poor survival and can be used as a prognostic factor in breast cancer.
    Fu D; Ren C; Tan H; Wei J; Zhu Y; He C; Shao W; Zhang J
    Medicine (Baltimore); 2015 Mar; 94(11):e637. PubMed ID: 25789956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased expression of SOX17 is associated with tumor progression and poor prognosis in breast cancer.
    Fu DY; Tan HS; Wei JL; Zhu CR; Jiang JX; Zhu YX; Cai FL; Chong MH; Ren CL
    Tumour Biol; 2015 Sep; 36(10):8025-34. PubMed ID: 25971583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer.
    Fu DY; Wang ZM; Li-Chen ; Wang BL; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2010 Feb; 119(3):601-12. PubMed ID: 19301122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival.
    Balgkouranidou I; Karayiannakis A; Matthaios D; Bolanaki H; Tripsianis G; Tentes AA; Lianidou E; Chatzaki E; Fiska A; Lambropoulou M; Kolios G; Kakolyris S
    Clin Chem Lab Med; 2013 Jul; 51(7):1505-10. PubMed ID: 23403728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer.
    Balgkouranidou I; Chimonidou M; Milaki G; Tsaroucha E; Kakolyris S; Georgoulias V; Lianidou E
    Clin Chem Lab Med; 2016 Aug; 54(8):1385-93. PubMed ID: 26741346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormal methylation of the sex-determining region Y-box 17 (SOX17) promoter predicts poor prognosis in myelodysplastic syndrome.
    Fan R; Zhao XL; Wang H; He HY; Peng ZP; Yang B; Han T; Wang W; Wang XQ; Lin GW
    Clin Lab; 2014; 60(9):1465-74. PubMed ID: 25291942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer.
    Chimonidou M; Strati A; Malamos N; Georgoulias V; Lianidou ES
    Clin Chem; 2013 Jan; 59(1):270-9. PubMed ID: 23136251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Role of RASSF1A, SOX17 and Wif-1 Promoter Methylation Status in Cell-Free DNA of Advanced Gastric Cancer Patients.
    Karamitrousis EI; Balgkouranidou I; Xenidis N; Amarantidis K; Biziota E; Koukaki T; Trypsianis G; Karayiannakis A; Bolanaki H; Kolios G; Lianidou E; Kakolyris S
    Technol Cancer Res Treat; 2021; 20():1533033820973279. PubMed ID: 33928818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer.
    Veeck J; Wild PJ; Fuchs T; Schüffler PJ; Hartmann A; Knüchel R; Dahl E
    BMC Cancer; 2009 Jul; 9():217. PubMed ID: 19570204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrantly hypermethylated tumor suppressor genes were identified in oral squamous cell carcinoma (OSCC).
    Kim SY; Han YK; Song JM; Lee CH; Kang K; Yi JM; Park HR
    Clin Epigenetics; 2019 Aug; 11(1):116. PubMed ID: 31405379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rapid and accurate closed-tube Methylation-Sensitive High Resolution Melting Analysis assay for the semi-quantitative determination of SOX17 promoter methylation in clinical samples.
    Mastoraki S; Chimonidou M; Dimitrakopoulos L; Kounelis S; Malamos N; Georgoulias V; Lianidou E
    Clin Chim Acta; 2015 Apr; 444():303-9. PubMed ID: 25727515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells.
    Chimonidou M; Strati A; Tzitzira A; Sotiropoulou G; Malamos N; Georgoulias V; Lianidou ES
    Clin Chem; 2011 Aug; 57(8):1169-77. PubMed ID: 21700955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer.
    Snider H; Villavarajan B; Peng Y; Shepherd LE; Robinson AC; Mueller CR
    Clin Epigenetics; 2019 Nov; 11(1):155. PubMed ID: 31675993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and clinicopathological significance of TMEFF2, SMOC-2, and SOX17 expression in endometrial carcinoma.
    Alabiad MA; Harb OA; Hefzi N; Ahmed RZ; Osman G; Shalaby AM; Alnemr AA; Saraya YS
    Exp Mol Pathol; 2021 Oct; 122():104670. PubMed ID: 34339705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy.
    Huang YT; Li FF; Ke C; Li Z; Li ZT; Zou XF; Zheng XX; Chen YP; Zhang H
    J Transl Med; 2013 Oct; 11():245. PubMed ID: 24090193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein expression and methylation of MGMT, a DNA repair gene and their correlation with clinicopathological parameters in invasive ductal carcinoma of the breast.
    Asiaf A; Ahmad ST; Malik AA; Aziz SA; Rasool Z; Masood A; Zargar MA
    Tumour Biol; 2015 Aug; 36(8):6485-96. PubMed ID: 25820821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wnt pathway antagonists, SFRP1, SFRP2, SOX17, and PPP2R2B, are methylated in gliomas and SFRP1 methylation predicts shorter survival.
    Majchrzak-Celińska A; Słocińska M; Barciszewska AM; Nowak S; Baer-Dubowska W
    J Appl Genet; 2016 May; 57(2):189-97. PubMed ID: 26337424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer.
    Akhoondi S; Lindström L; Widschwendter M; Corcoran M; Bergh J; Spruck C; Grandér D; Sangfelt O
    Breast Cancer Res; 2010; 12(6):R105. PubMed ID: 21122106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of expression and aberrant methylation of the CDH1 (E-cadherin) gene in breast cancer patients from Kashmir.
    Asiaf A; Ahmad ST; Aziz SA; Malik AA; Rasool Z; Masood A; Zargar MA
    Asian Pac J Cancer Prev; 2014; 15(15):6397-403. PubMed ID: 25124632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant PTPRO methylation in tumor tissues as a potential biomarker that predicts clinical outcomes in breast cancer patients.
    Li SY; Li R; Chen YL; Xiong LK; Wang HL; Rong L; Luo RC
    BMC Genet; 2014 Jun; 15():67. PubMed ID: 24919593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.